Investment Profile
The primary focus of the Group’s activities is on projects with an anticipated 4-6 year development track from their inception to commercialization.
Adiuvo’s business model includes the validation of non-medicinal products using procedures to obtain data that make it possible to confirm pro-health effects, enhance treatment outcomes, or prevent the progression of a disease. Such products can be sold with confirmed health indications (nutraceuticals) or certificates permitting their use by patients (patient monitoring) after the performance of clinical studies.
This, along with protected intellectual property rights, provides the Company with competitive advantages and, as a result, attracts the interest of leaders in the sector.
Currently, Adiuvo is developing more than 25 projects by means of two platforms:
Nutraceuticals Platform
Products developed within the nutraceuticals platform address the growing demand for high quality over-the-counter products with clinically proven efficacy, aimed at improving the general health and delaying the onset of disease and the symptoms of ageing. Adiuvo focuses on the development and launch of nutraceuticals and functional foods, the effects of which are confirmed by clinical studies under pharmaceutical rigor, and which have protected intellectual property rights on a number of important markets.
Studies documenting the biological activity of the products developed are conducted following a methodology used in pharma (in terms of pharmacokinetic and clinical efficacy studies), which considerably increases their attractiveness to both users and potential industrial partners and distributors.
Medical Devices and Digital Health Platform
Adiuvo focuses mainly on the development of next-generation sensors and technologies based on nanosensors, Micro-electronic Mechanical Systems technology, and next-generation materials. Products containing new sensors must undergo a registration procedure by the European Medicines Agency and its equivalent in the USA, the FDA, in order to be approved for use in medical procedures as a means of supporting standard therapy. The Group is particularly interested in self-monitoring devices, designed for both healthy people (sports, monitoring of basic biochemical parameters), and sick people (disease management by monitoring functional and biochemical parameters influenced by drug products). This type of data acquisition improves therapy customization and allows the patient to participate in disease prevention and the treatment process, which is of growing importance in new approaches to health and therapy management.
